Custom service
PEGylation Services
Longer circulation, less aggregation — without burying the active site.
PEGylation changes what a protein does in a body and in a vial. In circulation, a PEG chain extends half-life by shielding the protein from proteases and renal clearance. In formulation, it reduces aggregation and increases solubility. Both effects are real, and both are lost if the PEG attaches to the wrong place — covering the active site or destabilising the fold.
Site selection is the engineering. Random NHS chemistry through surface lysines is fast and adequate for proteins with many accessible lysines and a forgiving surface. Site-specific conjugation — through an engineered cysteine, an enzymatic tag or a glycan remodelling — places the polymer deliberately, away from functional surfaces and at a defined stoichiometry. The choice is made against the protein and the application, and the rationale is documented.
Characterisation defines the product. PEGylation degree is measured by MALDI-TOF or SEC-MALS; activity is measured against the unmodified protein; and aggregation is measured by SEC, because a heavily PEGylated protein can hide aggregates behind the polymer's large apparent mass. The batch certificate states conjugation degree, activity retention and monomer content together.
PEGylation is used for proteins intended for in vivo work — half-life extension, immunogenicity reduction — and for proteins that aggregate at the concentration an assay or formulation requires.
It is not appropriate for assays where the polymer's mass interferes with the measurement, or where the protein's activity depends on a surface too large to leave free. A failed PEGylation campaign is usually a site-selection problem, caught early by comparing variants.
Every lot is released with conjugation degree, activity retention relative to the unmodified protein, SEC-HPLC monomer and aggregate content, and endotoxin where in vivo use is intended. The unmodified parent is retained as a reference for future comparison.
Service Highlights
- PEG size and architecture options. Linear and branched PEG from 2 to 40 kDa, selected against the required half-life extension and viscosity impact.
- Site-specific conjugation. Engineered cysteine, sortase, transglutaminase or glycan-based attachment with defined stoichiometry.
- Random chemistry where appropriate. NHS PEGylation with conjugation degree controlled by reagent ratio and verified per lot.
- Activity retained by design. PEG placed away from the binding or catalytic surface, verified by activity assay against the parent.
- Aggregation behaviour measured. SEC after conjugation, so the claimed solubility benefit is demonstrated rather than asserted.
- Linker variants tested. Several attachment sites and PEG sizes compared in one campaign to find the conjugate that works.
How the work runs
Site and PEG selection
Attachment site chosen from structure; PEG size and architecture selected against the application's requirements.
Chemistry setup
Site-specific handle engineered or random chemistry conditions optimised for the target conjugation degree.
Conjugation
Reaction run at analytical scale first, then preparative under the selected condition.
Purification
Free PEG and unconjugated protein removed by SEC or ion exchange.
Characterisation
Conjugation degree by MALDI-TOF or SEC-MALS, activity against parent, monomer content by SEC.
Lot release
Certificate with conjugation degree, activity retention, purity and recommended storage.
Specifications & timeline
- PEG sizes
- 2, 5, 10, 20, 40 kDa; linear and branched
- Chemistry
- NHS-ester, maleimide-thiol, aldehyde, click (azide/alkyne), enzymatic
- Conjugation degree
- 1–4 PEG per protein, measured per lot
- Characterisation
- MALDI-TOF, SEC-MALS, SDS-PAGE, activity, SEC-HPLC
- Timeline
- 2–4 weeks per conjugate
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.